Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: An open-label, non-inferiority, randomised, controlled trial

The Lancet Infectious Diseases

Volumn 15, Issue 8, 2015, Pages 898-904

  Estívariz, Concepción F ^a   Anand, Abhijeet ^a   Gary, Howard E ^a   Rahman, Mahmudur ^b   Islam, Jannatul ^c   Bari, Tajul I ^d   Wassilak, Steven G F ^a   Chu, Susan Y ^a   Weldon, William C ^a   Pallansch, Mark A ^a   Heffelfinger, James D ^a,c   Luby, Stephen P ^a,c   Zaman, Khalequ ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Disease Control and Research   (Bangladesh)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d WHO Bangladesh   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BANGLADESH; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DOSE; FEEDING DISORDER; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN POLIOVIRUS 1; HUMAN POLIOVIRUS 2; HUMAN POLIOVIRUS 3; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; OPEN STUDY; OUTCOME ASSESSMENT; PNEUMONIA; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SEROCONVERSION; SEROPREVALENCE; VOMITING; ANTIBODY PRODUCTION; CLINICAL TRIAL; IMMUNOLOGY; INFANT; POLIOMYELITIS; PROCEDURES; VACCINATION;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; BANGLADESH; HUMANS; IMMUNIZATION SCHEDULE; INFANT; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84937727941     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00094-8     Document Type: Article

References (30)

1. Patriarca PA, Wright PF, John TJ Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13:926-939.
2. Aylward RB Eradicating polio: today's challenges and tomorrow's legacy. Ann Trop Med Parasitol 2006, 100:401-413.
3. Birmingham ME, Aylward RB, Cochi SL, Hull HF National immunization days: state of the art. J Infect Dis 1997, 175(suppl 1):S183-S188.
4. Patriarca PA, Linkins RW, Sutter RW, Orenstein WA Optimal schedule for the administration of oral poliovirus vaccine. Measles and poliomyelitis 1993, 303-313. Springer-Verlag, Austria. E. Kurstak (Ed.).
5. Caceres VM, Sutter RW Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001, 33:531-541.
6. el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Eng J Med 2008, 359:1655-1665.
7. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.
8. Bahl S, Estivariz CF, Sutter RW, et al. Cross-sectional serologic assessment of immunity to poliovirus in high risk areas of Northern India. J Infect Dis 2014, 210(suppl 1):S243-S251.
9. Data and monitoring The Global Polio Eradication Initiative, (accessed Aug 7, 2014). http://www.polioeradication.org.
10. Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013, 3:309-315.
11. Diop OM, Burns C, Wassilak SG, Kew OM Update on vaccine-derived polioviruses-worldwide, July 2012-December 2013. MMWR Morb Mortal Wkly Rep 2014, 63:242-248.
12. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 2005, 59:587-635.
13. Polio eradication and endgame strategic plan 2013-18 The Global Polio Eradication Initiative, (accessed Aug 8, 2014). http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf.
14. Meeting of the Strategic Advisory Group of Experts on immunization, Nov, 2012-conclusions and recommendations. Wkly Epidemiol Rec 2013, 88:1-16. WHO.
15. Progress toward poliomyelitis eradication-Afghanistan, January 2012-September 2013. MMWR Morb Mortal Wkly Rep 2013, 62:928-933. Centers for Disease Control and Prevention.
16. Progress toward poliomyelitis eradication-Pakistan, January 2012-September 2013. MMWR Morb Mortal Wkly Rep 2013, 62:934-938. Centers for Disease Control and Prevention.
17. Moturi EK, Porter KA, Wassilak SG, et al. Progress toward polio eradication-worldwide, 2013-2014. MMWR Morb Mortal Wkly Rep 2014, 63:468-472.
18. Yakovenko ML, Gmyl AP, Ivanova OE, et al. The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt. Euro Surveill 2014, 19:20706.
19. Multicentre growth reference study group: WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development 2006, WHO, World Health Organization, Geneva, (accessed Feb 21, 2013). http://www.who.int/childgrowth/standards/technical_report/en/index.html.
20. Safey of injections: WHO-UNICEF policy statement for mass immunization campaigns. Nov, 1997 1997, WHO, World Health Organization, Geneva.
21. Report of a WHO Informal consultation on polio neutralizing antibody assays, Nashville, Dec 5-6, 1991 1991, Expanded programme on immunization, World Health Organization, Geneva.
22. Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997, 175(suppl 1):S258-S263.
23. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia. J Infect Dis 1995, 171:1097-1106. WHO collaborative study group on oral poliovirus vaccine.
24. SAS/STAT user's guide, version 6.4 1989, SAS Institute, SAS Institute, Cary, NC. 4th edn.
25. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009, 27:1333-1339.
26. Haque R, Snider C, Liu Y, et al. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine 2014, 32:478-482.
27. Patel M, Steele AD, Parashar UD Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012, 30(suppl 1):A30-A35.
28. Pagano JS, Plotkin SA, Koprowski H Variations in the responses of infants to live attenuated poliovirus vaccines. N Eng J Med 1961, 264:155-163.
29. Smorodintsev AA, Drobyshevskaya AI, Bulychev NP, et al. Material on the immunological and epidemiological effectiveness of live poliomyelitis vaccine. Panamerican Health Organization. Second international conference on live poliovirus vaccines 1960, 482-499. Panamerican Health Organization, Washington DC.
30. Health and Demographic surveillance system-Matlab-volume 45. Registration of health and demographic events, 2011. Scientific report no. 121, Dec, 2012. iccdr,b, ed International Center for Diarrhoeal Diseases Research B, (accessed April 23, 2014). http://www.icddrb.org/what-we-do/publications/cat_view/52-publications/10043-icddrb-documents/10049-hdss-annual-reports/14338-hdss-annual-report-2011-sr121.